Related Experiment Video

Updated: Aug 29, 2025

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair
08:15

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair

Published on: October 6, 2014

12.3K

PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and Beyond

Maria Clara Saad Menezes1, Farah Raheem2, Lida Mina2

  • 1Harvard T.H. Chan School of Public Health, 677 Huntington Ave, Boston, MA 02115, USA.

Cancers
|September 9, 2022
PubMed

Insights

Poly-adenosine diphosphate ribose polymerase (PARP) inhibitors are effective for BRCA1/2 carriers with breast cancer. Their use is expanding to other cancers and biomarkers, showing broader therapeutic potential.

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Poly-adenosine diphosphate ribose polymerase (PARP) inhibitors (PARPi) are approved for HER2-negative breast cancer patients with BRCA1/2 mutations, particularly those at high risk of recurrence or with metastatic disease.
  • The therapeutic landscape for PARPi extends beyond breast cancer, encompassing other malignancies like prostate and ovarian cancers.

Purpose of the Study:

  • To summarize current data on PARPi efficacy in breast cancer.
  • To explore the expanding indications for PARPi in oncology, including other cancer types and biomarkers.

Main Methods:

  • Literature review of clinical trial data and research studies on PARPi in breast cancer and other malignancies.
  • Analysis of biomarker data (e.g., BRCA1/2, ATM, PALB2, CHEK) and genomic instability scores associated with PARPi response.

Main Results:

  • PARPi demonstrate significant benefit in BRCA1/2-mutated breast cancer across adjuvant and metastatic settings.
  • Emerging evidence supports PARPi utility in other cancers, linked to a wider range of biomarkers and genomic profiles.

Conclusions:

  • PARPi represent a crucial therapeutic class for BRCA1/2-mutated breast cancer.
  • The application of PARPi is broadening, offering potential benefits for a wider patient population based on diverse biomarkers and genomic characteristics.
Keywords:
BRCA1BRCA2HRDPALB2PARPibreast cancerhomologous recombination repair

More Related Videos

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

9.2K
Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging06:44

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging

Published on: April 28, 2021

4.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Long-patch Base Excision Repair01:02

Long-patch Base Excision Repair

Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are:
7.1K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K